Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 5 | 8 |
| List of Tables | 8 | 2 |
| List of Figures | 10 | 3 |
| Introduction | 13 | 1 |
| Biosimilars in Developed Countries- Market Overview | 14 | 8 |
| Introduction | 14 | 1 |
| Biologics and Small Molecules | 15 | 1 |
| Structural Differences between Biologics and Small Molecules | 15 | 1 |
| Market Size and Patent Expiries of Branded Biologics | 16 | 1 |
| Market Size of Branded Biologics &Sales by Major Drug Classes in 2010 | 16 | 1 |
| Top Ten Biologics in 2010 | 17 | 1 |
| Patent Expiry of Leading Biologics, 2011 2018 | 18 | 1 |
| Approved Biosimilars in Europe until December 2011 | 19 | 1 |
| Biopharmaceutical and Biosimilars Manufacturing and Development Process | 20 | 1 |
| Manufacturing Process | 20 | 1 |
| Setting up a new biosimilar manufacturing facility | 21 | 1 |
| Development Process &Cost | 21 | 1 |
| Biosimilars in Developed Countries- Geographic Landscape | 22 | 48 |
| Introduction | 22 | 1 |
| Global Biosimilar Market | 23 | 1 |
| Market Size and Forecast | 23 | 2 |
| Drivers and Barriers | 25 | 1 |
| US Biosimilar Market | 26 | 1 |
| Market Size and Forecast | 26 | 2 |
| Regulatory Landscape | 28 | 1 |
| Objectives of Biosimilar Legislation and Regulatory Frameworks | 29 | 1 |
| Comparison of the biosimilar with reference biologic | 29 | 1 |
| Level of clinical trial data and duration of the study adequate for the biosimilar approval | 29 | 1 |
| Prerequisites for post-marketing safety evaluation studies | 29 | 1 |
| Standards and criteria for the interchangeability of the biosimilar | 29 | 1 |
| Incentives to innovator company R&D through Intellectual Property protection and market exclusivity. | 29 | 1 |
| Regulatory Framework for Biopharmaceutical Industry | 30 | 3 |
| Evolution of Regulatory Pathways for Biosimilars | 33 | 3 |
| BPCI Act and the Pathway for Approval of Biosimilar Products | 36 | 1 |
| Biosimilarity vs. Interchangeability | 36 | 1 |
| FDA Guidance Documents | 36 | 1 |
| Contents of the Biosimilar Application - Clinical Studies | 37 | 1 |
| Differences between Biosimilar and Interchangeable Biosimilar Products | 37 | 1 |
| Market and Data Exclusivity | 38 | 1 |
| Patent Dispute Procedure | 38 | 2 |
| Notice of Commercial Marketing | 40 | 1 |
| Other Provisions | 40 | 1 |
| Substitution is a Decision Taken at Local Level | 41 | 1 |
| Drivers and Barriers | 42 | 1 |
| Top Five European Markets- Biosimilar Market Size and Forecast | 43 | 1 |
| Introduction | 43 | 1 |
| Market Size and Forecast | 43 | 2 |
| Regulatory Framework for Biopharmaceutical Industry | 45 | 1 |
| Evolution of Regulatory Pathways for Biosimilars | 46 | 1 |
| Current Position on Biosimilars | 47 | 1 |
| Overarching Guidelines | 47 | 1 |
| Quality Guidelines | 47 | 1 |
| Non-Clinical and Clinical Guidelines | 48 | 1 |
| Annexes Product Specific Guidelines | 48 | 1 |
| Post-Authorization Requirements | 48 | 1 |
| Data Exclusivity Period | 49 | 1 |
| What does this mean for the biosimilar industry? | 49 | 1 |
| The Bolar Type Provision | 50 | 1 |
| The Comparability Exercise | 50 | 2 |
| Biosimilars Approvals and Applications | 52 | 2 |
| EMA Guidelines for Biosimilar mAb | 54 | 1 |
| European Biosimilars Industry- Issues | 54 | 1 |
| Naming | 55 | 1 |
| Labeling | 55 | 1 |
| Substitution/Interchangeability | 55 | 1 |
| Pharmacovigilance | 55 | 1 |
| Drivers and Barriers | 56 | 1 |
| Country Analysis The UK | 57 | 1 |
| Structure of the Healthcare System | 57 | 1 |
| Pricing and Reimbursement Mechanisms | 57 | 1 |
| Drivers and Barriers for Biosimilars | 58 | 1 |
| Country Analysis Germany | 58 | 1 |
| Structure of the Healthcare System | 58 | 1 |
| Pricing and Reimbursement Mechanisms | 59 | 1 |
| Drivers and Barriers for Biosimilars | 59 | 1 |
| Country Analysis France | 60 | 1 |
| Structure of the Healthcare System | 60 | 1 |
| Pricing and Reimbursement Mechanisms | 60 | 1 |
| Drivers and Barriers for Biosimilars | 61 | 1 |
| Country Analysis Spain | 62 | 1 |
| Structure of the Healthcare System | 62 | 1 |
| Pricing and Reimbursement Mechanisms | 62 | 1 |
| Drivers and Barriers for Biosimilars | 63 | 1 |
| Country Analysis Italy | 64 | 1 |
| Structure of the Healthcare System | 64 | 1 |
| Pricing and Reimbursement Mechanisms | 64 | 1 |
| Drivers and Barriers for Biosimilars | 64 | 1 |
| Japan Biosimilars Market Size and Forecasts | 65 | 1 |
| Market Size and Forecast | 65 | 1 |
| Regulatory Landscape in Japan | 66 | 1 |
| Regulatory Framework for Biopharmaceutical Industry | 66 | 1 |
| Evolution of Regulatory Pathways for Biosimilars | 67 | 1 |
| Current Position on Biosimilars | 68 | 1 |
| Approved Biosimilars | 68 | 1 |
| Drivers and Barriers | 69 | 1 |
| Biosimilars in Developed Countries Market Characterization | 70 | 28 |
| Human Growth Hormone Biosimilars Market | 70 | 1 |
| Pipeline molecules | 71 | 1 |
| Drivers and barriers | 72 | 1 |
| Erythropoietin (EPO) Biosimilars Market | 73 | 2 |
| Pipeline molecules | 75 | 1 |
| Drivers and barriers | 76 | 1 |
| Granulocyte-Colony Stimulating Factor (G-CSF) Biosimilars Market | 77 | 2 |
| Pipeline molecules | 79 | 1 |
| Drivers and barriers | 80 | 1 |
| Interferon alpha Biosimilars Market | 81 | 1 |
| Pipeline molecules | 82 | 1 |
| Interferon beta Biosimilars Market | 82 | 1 |
| Pipeline molecules | 83 | 1 |
| Interferon alpha and Interferon beta Drivers and Barriers | 84 | 1 |
| Insulin and Insulin Analogs Biosimilars Market | 85 | 2 |
| Pipeline molecules | 87 | 1 |
| Drivers and barriers | 88 | 1 |
| TNF-alpha Inhibitor Biosimilars Market | 89 | 2 |
| Pipeline molecules | 91 | 1 |
| Drivers and barriers | 92 | 1 |
| Biosimilars Market for Monoclonal Antibodies against Cancer | 93 | 2 |
| Pipeline molecules | 95 | 2 |
| Drivers and barriers | 97 | 1 |
| Biosimilars in Developed Countries- Case Study | 98 | 11 |
| Market Share of Biosimilars in Top Five European Markets | 98 | 1 |
| Market Share Filgrastim | 98 | 1 |
| Market Share- Somatropin | 98 | 1 |
| Market Share- EPO | 99 | 1 |
| Pricing of Biosimilars in Top Five European Markets | 100 | 2 |
| Strategies Adopted By Branded Biologic Companies to Beat Generic Competition | 102 | 1 |
| Introduction | 102 | 1 |
| Second Generation Biologics | 102 | 1 |
| New Formulation | 103 | 1 |
| Combination Products | 103 | 1 |
| New Approved Indications | 104 | 1 |
| Caps | 104 | 1 |
| Industry Dynamics- Strategies to Be Adopted by Companies to Enter the Biosimilar Market | 105 | 1 |
| Product | 106 | 1 |
| Regulatory and Clinical Expertise | 106 | 1 |
| Capital Investment | 106 | 1 |
| Manufacturing Capability | 106 | 1 |
| Price | 106 | 1 |
| Discount to originator | 106 | 1 |
| Reimbursement | 106 | 1 |
| Competitors Pricing | 107 | 1 |
| Place | 107 | 1 |
| Market Segment to Target | 107 | 1 |
| Prescribing trends | 107 | 1 |
| Sustainability of originator | 107 | 1 |
| Promotion | 107 | 1 |
| Customized Sales and Marketing | 107 | 1 |
| Differentiation | 108 | 1 |
| People | 108 | 1 |
| Decision Makers- Prescribers | 108 | 1 |
| Decision Makers- Payers | 108 | 1 |
| Biosimilars in Developed Countries-Competitive Landscape | 109 | 9 |
| Celltrion | 109 | 1 |
| Company Profile | 109 | 1 |
| SWOT Analysis | 109 | 1 |
| Dr Reddy s Laboratories | 110 | 1 |
| Company Profile | 110 | 1 |
| SWOT Analysis | 110 | 1 |
| Hospira | 111 | 1 |
| Company Profile | 111 | 1 |
| SWOT Analysis | 111 | 1 |
| Biocon | 112 | 1 |
| Company Profile | 112 | 1 |
| SWOT Analysis | 112 | 1 |
| Teva Pharmaceuticals Ltd | 113 | 1 |
| Company Profile | 113 | 1 |
| SWOT Analysis | 113 | 1 |
| Sandoz | 114 | 1 |
| Company Profile | 114 | 1 |
| SWOT Analysis | 114 | 1 |
| 3SBio | 115 | 1 |
| Company Profile | 115 | 1 |
| SWOT Analysis | 115 | 1 |
| Intas Pharma | 116 | 1 |
| Company Profile | 116 | 1 |
| SWOT Analysis | 116 | 1 |
| Samsung Biologics | 117 | 1 |
| Company Profile | 117 | 1 |
| SWOT Analysis | 117 | 1 |
| Biosimilars in Developed Countries- Strategic Consolidations | 118 | 16 |
| Deals by Type | 118 | 1 |
| Mergers &Acquisitions (M&A) | 119 | 1 |
| M&A Deals by Year | 119 | 1 |
| M&A Deals by Value | 120 | 1 |
| M&A Deals by Geography | 121 | 1 |
| M&A Deals in 2011 | 122 | 1 |
| SemBioSys Genetics Completes Private Placement of Bonds for $4.01m | 122 | 1 |
| Therapeutic Proteins Secures $2.5m in the Second Tranche of Venture Financing Round | 122 | 1 |
| Teva Completes Acquisition of Cephalon | 122 | 1 |
| Licensing Agreements in the Biosimilars Market | 123 | 1 |
| Licensing Agreements By Year | 123 | 1 |
| Licensing Agreements By Value | 124 | 1 |
| Licensing Agreements By Geography | 125 | 1 |
| Licensing Agreement Deals | 126 | 1 |
| Richter Gedeon Enters Into Licensing Agreement With STADA Arzneimittel For Rituximab | 126 | 1 |
| Richter Gedeon Enters Into Licensing Agreement With STADA Arzneimittel For Trastuzumab | 126 | 1 |
| Hanwha Chemical Enters Into Licensing Agreement With Merck For HD203 | 127 | 1 |
| Compass Biotechnologies Enters Into Licensing Agreement With Arecor | 127 | 1 |
| Viropro Enters Into Licensing Agreement With Spectrum Pharmaceuticals For Rituximab | 127 | 1 |
| Co- Development Deals | 128 | 1 |
| Co-Development Deals By Year | 128 | 1 |
| Co-Development Deals By Value | 129 | 1 |
| Co-Development Deals By Geography | 130 | 1 |
| Co-Development Deals | 131 | 1 |
| Amgen Enters Into Co-Development Agreement With Watson For Generic Cancer Drugs | 132 | 1 |
| Samsung Forms Joint Venture With Biogen Idec For Biosimilars | 132 | 1 |
| Samsung and Quintiles Team Up for Co-Development of Biosimilar | 132 | 1 |
| Baxter International Enters Into Co-Development Agreement with Momenta Pharmaceuticals for Biologics | 133 | 1 |
| Biosimilars in Developed Countries- Appendix | 134 | 8 |
| Market Definitions | 134 | 1 |
| Abbreviations | 135 | 2 |
| Bibliography | 137 | 2 |
| Research Methodology | 139 | 3 |
| Market Overview | 140 | 1 |
| Methodology | 140 | 1 |
| Sources of Coverage | 140 | 1 |
| Geographic Landscape | 140 | 1 |
| Methodology | 140 | 1 |
| Sources of Coverage | 140 | 1 |
| Market Characterization | 140 | 1 |
| Methodology | 140 | 1 |
| Sources of Coverage | 140 | 1 |
| Case Study | 141 | 1 |
| Methodology | 141 | 1 |
| Sources of Coverage | 141 | 1 |
| Competitive Landscape | 141 | 1 |
| Methodology | 141 | 1 |
| Sources of Coverage | 141 | 1 |
| Strategic Consolidations | 141 | 1 |
| Methodology | 141 | 1 |
| Sources of Coverage | 141 | 1 |
| Contact Us | 141 | 1 |
| Disclaimer | 141 | 1 |